Polymer particles

Patent metadata

Field	Value
Publication number	US-11110198-B2
Application number	US-202016821783-A
Country	US
Kind code	B2
Filing date	Mar 17, 2020
Priority date	Sep 28, 2016
Publication date	Sep 7, 2021
Grant date	Sep 7, 2021

Abstract

Biodegradable, cross-linked polymer particle embolics and methods of making the same are described. The particle embolics can be used as embolization agents.

First claim

We claim:

1. An embolic composition including:
polymer particles comprising at least one monomer including at least one functional group, at least one crosslinker having a structure

at least one pharmaceutical agent.

2. The embolic composition of claim 1 , wherein the at least one pharmaceutical agent is a positively charged pharmaceutical agent.

3. The embolic composition of claim 1 , wherein the at least one pharmaceutical agent is a negatively charged pharmaceutical agent.

4. The embolic composition of claim 1 , wherein the at least one pharmaceutical agent is irinotecan, doxorubicin, epirubicin, idarubicin, or a combination thereof.

5. The embolic composition of claim 1 , wherein the polymer particles have a diameter between about 40 μm and about 1,200 μm.

6. The embolic composition of claim 1 , wherein the polymer particles have a diameter between about 75 μm and about 1,200 μm.

7. The embolic composition of claim 1 , wherein the at least one functional group is acrylate, acrylamide, methacrylate, or methacrylamide.

8. The embolic composition of claim 1 , wherein the at least one monomer includes an ionizable functional group.

9. The embolic composition of claim 8 , wherein the ionizable functional group is basic.

10. The embolic composition of claim 8 , wherein the ionizable functional group is acidic.

11. The embolic composition of claim 1 , wherein the polymer particles include a second crosslinker including a second linkage selected from an ester, a thioester, a carbonate, a peptide cleavable by matrix metalloproteinases, a peptide cleavable by matrix collagenases, a peptide cleavable by matrix elastases, and a peptide cleavable by matrix cathepsins.

12. The embolic composition of claim 1 , wherein the polymer particles are biodegradable.

13. The embolic composition of claim 1 , wherein the polymer particles are substantially degraded within about 1 months of implantation.

14. The embolic composition of claim 1 , wherein the at least one monomer is dimethylacrylamide.

15. The embolic composition of claim 1 , wherein the at least one monomer is acrylamide.

16. The embolic composition of claim 1 , wherein the at least one pharmaceutical agents is at least 90% eluted over the first day of implantation.

17. The embolic composition of claim 1 , wherein the at least one pharmaceutical agents is at least 60% eluted over the first day of implantation.

18. The embolic composition of claim 1 , wherein the at least one pharmaceutical agent is at a highest concentration in situ less than about 1 hour after implantation.

19. A method of treatment, the method comprising:
delivering the embolic solution of claim 1 through a delivery device to a treatment site.

20. The method of claim 19 , wherein the delivering is through a catheter, a microcatheter, or a needle.

Assignees

• Terumo Corp

Inventors

• Hincapie Gloría
• Wu Xinping
• Wu Yue
• Cruise Gregory M

Classifications

• C08L2203/02

  for biomedical use · CPC title

• C08L33/26

  Homopolymers or copolymers of acrylamide or methacrylamide · CPC title

• A61L26/009

  Materials resorbable by the body · CPC title

• A61L26/0066

  Medicaments; Biocides · CPC title

• A61L26/0014

  obtained by reactions only involving carbon-to-carbon unsaturated bonds · CPC title